We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
In the latest trading session, Humacyte, Inc. (HUMA - Free Report) closed at $0.41, marking a -13.01% move from the previous day. This move lagged the S&P 500's daily loss of 1.82%. Meanwhile, the Dow experienced a drop of 1.09%, and the technology-dominated Nasdaq saw a decrease of 2.86%.
The company's shares have seen a decrease of 6.58% over the last month, not keeping up with the Medical sector's gain of 5.28% and the S&P 500's gain of 0.71%.
Investors will be eagerly watching for the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.09, indicating a 35.71% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $0.86 million, indicating a 14.67% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.4 per share and a revenue of $4.05 million, demonstrating changes of -53.85% and +98.48%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Humacyte, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Humacyte, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 103, this industry ranks in the top 42% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HUMA in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Humacyte, Inc. (HUMA - Free Report) closed at $0.41, marking a -13.01% move from the previous day. This move lagged the S&P 500's daily loss of 1.82%. Meanwhile, the Dow experienced a drop of 1.09%, and the technology-dominated Nasdaq saw a decrease of 2.86%.
The company's shares have seen a decrease of 6.58% over the last month, not keeping up with the Medical sector's gain of 5.28% and the S&P 500's gain of 0.71%.
Investors will be eagerly watching for the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.09, indicating a 35.71% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $0.86 million, indicating a 14.67% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.4 per share and a revenue of $4.05 million, demonstrating changes of -53.85% and +98.48%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Humacyte, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Humacyte, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 103, this industry ranks in the top 42% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HUMA in the coming trading sessions, be sure to utilize Zacks.com.